

Global Cell and Gene Therapy Market

Market Research Report | 2024-03-21 | 145 pages | BCC Research

AVAILABLE LICENSES:

- Single User License \$5500.00
- 2-5 Users License \$6600.00
- Site License \$7920.00
- Enterprise License \$9504.00

Report description:

Description

Report Scope:

The scope of this study encompasses an investigation of the cell and gene therapy market. BCC Research analyzes cell and gene therapy market based on therapy type, product, application, and region. BCC determines the current market status in each segment, examines its impact on future needs, and presents growth forecasts over the next five years. The report provides a detailed analysis of the market's drivers, challenges, and opportunities. The report also covers market projections for 2028 and market shares for key market players. The report includes the company profiles of the key players with detailed information about their business segments, financials, product portfolios, and recent developments. The report also provides information on the emerging technologies, and new developments, ESG development and investment outlook.

Report Includes:

- 55 data tables and 26 additional tables

- An overview of the global market for cell and gene therapy

- Analysis of global market trends, featuring historical revenue data for 2020, 2021, and 2022, estimated figures for 2023, forecasts for 2028, and projections of compound annual growth rates (CAGRs) through 2028

- Evaluation of the current market's size and revenue growth prospects specific to cell and gene therapy, along with a market share analysis by therapy type, product, application, and geographic region

- An update on recent advances in vector biology, drug delivery technology and gene editing technologies such as CRISPR

- Coverage of novel therapeutic products and promising new technologies still in the development and testing stage, with as assessment of the probability that they will be commercialized successfully in the next five years

- Discussion on recent approvals, developments, emerging technologies, ESG, and an investment outlook

- Profiles of leading market participants, including Mallinckrodt PLC, Vericel Corp., Gilead Sciences Inc., Pharmicell Co. Ltd., and Bristol-Myers Squibb Co.

Executive Summary

Summary:

The total global market for cell and gene therapy was valued at \$5.8 billion in 2022 and this market is anticipated to reach \$23.3 billion by 2028.

The global cell and gene therapy market is anticipated to grow at a CAGR of 26.4% during the forecast period of 2023-2028. The increasing focus on developing advanced therapies for different therapeutic areas, and growing prevalence of chronic conditions such as cancer and rare diseases, are responsible for market growth.

The market has witnessed approval of therapies in 2022 and 2023. Treatments approved in 2022 include Adstiladrin from Ferring Pharmaceuticals, Hemgenix from CSL Behring and UniQure, Roctavian from Biomarin Pharmaceuticals, Elevidys from Sarepta and Roche, and Upstaza from PTC Therapeutics. Vyjuvek from Krystal Biotech and Lyfgenia from Bluebird Bio were approved in 2023. There are more companies which have submitted biologics license applications for their cell and gene therapy products and the approvals are expected in 2024, thus contributing to the growth of the market.

Products such as Kresladi from Rocket Pharmaceuticals and Fidanacogene elaparvovec from Pfizer have submitted the biologics license application (BLA) and are likely to get approval in March and April 2024.

Table of Contents:

Table of Contents Chapter 1 Executive Summary Market Outlook Scope of Report Market Summary Market Value Chapter 2 Market Overview Cell and Gene Therapy Overview Regulatory Landscape U.S. (FDA) Europe Chapter 3 Market Dynamics Market Dynamics Market Drivers Market Restraints Market Opportunities Chapter 4 Market Segmentation Analysis Segmentation Breakdown Global Market for Cell and Gene Therapy Market Size and Forecast Market Analysis **Cell Therapy** Gene-modified Cell Therapy

Gene Therapy Global Market for Gene-modified Cell Therapy and Gene Therapy by Vector Type Market Size and Forecast Market Analysis Adeno-Associated Viral (AAV) Vectors **Retroviral Vectors** Lentiviral Vectors Others Global Market for Cell and Gene Therapy by Drug Product Market Size and Forecast Zolgensma Yescarta Kymriah Abecma Maci Tecartus Epicel Others Global Market for Cell and Gene Therapy by Application Market Size and Forecast Oncology **Rare Diseases** Ophthalmology Other Therapeutic Areas Geographic Breakdown Global Market for Cell and Gene Therapy by Region Market Size and Forecast North America Market Size and Forecast U.S. Canada Mexico Europe Market Size and Forecast Germany U.K. France Rest of Europe Asia-Pacific Market Size and Forecast Japan Cina Australia **Rest of Asia-Pacific** Rest of the World Market Size and Forecast Chapter 5 Competitive Intelligence

Investment Outlook Mergers and Acquisitions Competitive Landscape: Overview Market Share Analysis Strategic Acquisitions and Collaborations **Pipeline Analysis** Chapter 6 Sustainability: An ESG Perspective Introduction Conclusion Chapter 7 Appendix Methodology **Company Profiles** AMGEN INC. BLUEBIRD BIO INC. BRISTOL-MYERS SQUIBB CO. DENDREON PHARMACEUTICALS LLC FERRING PHARMACEUTICALS GILEAD SCIENCES INC. IOVANCE BIOTHERAPEUTICS INC. JOHNSON & JOHNSON SERVICES INC. KRYSTAL BIOTECH INC. MALLINCKRODT PLC NOVARTIS AG ORCHARD THERAPEUTICS PLC. PHARMICELL CO. LTD. UNIQURE N.V. VERICEL CORP. Abbreviations References



Global Cell and Gene Therapy Market

Market Research Report | 2024-03-21 | 145 pages | BCC Research

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License		Price
	Single User License		\$5500.00
	2-5 Users License		\$6600.00
	Site License		\$7920.00
	Enterprise License		\$9504.00
		VAT	
		Total	

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346. [** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	Phone*	
First Name*	Last Name*	
Job title*		
Company Name*	EU Vat / Tax ID / NIF	P number*
Address*	City*	
Zip Code*	Country*	
	Date	2025-05-06

Signature